Author:
Lahaniatis John E.,Brady Luther W.
Publisher
Springer Berlin Heidelberg
Reference25 articles.
1. Bigner DD, Brown MT, Friedman AH, et al. (1998) Iodine-131-abeled antitenascin monoclonal antibody 81c6 treatment of patients with malignant gliomas: phase I trial results. J Clin Oncol 16(6):2202–2212
2. Boiardi A, Silvanni A, Ruffini PA, et al. (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphocyte activated killer cell (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193–197
3. Bourdon MA, Coleman RE, Blasberg RG, et al. (1984) Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4:133–140
4. Brady LW, et al. (1990) Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 24:151–160; discussion 151–160
5. Brown MT, Coleman RE, Friedman AH, et al. (1996) Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 2(6):963–972